A Phase I Combined Pharmacokinetic and Efficacy Trial of Ivectosol Sublingual Wafers in COVID-19 Infected Patients
Latest Information Update: 24 May 2021
At a glance
- Drugs Ivermectin (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 24 May 2021 New trial record
- 18 May 2021 According to a Mountain Valley media release, the company will immediately pursue a combined pharmacokinetic and phase one human trial .The new human studies are anticipated to include the triple-mutant India variant B.1.617.